Navigation Links
BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Date:9/19/2008

the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... ( www.aapc.com ) announced its 2012 medical coding books ... previous year. Prices have been reduced more than 55 percent over ... reduction was to benefit our more than 100,000 members, non-members of ... Starynskaya, coding books department manager for of AAPC. ...
... (NASDAQ: ITMN ) today announced that it will ... open of the U.S. markets on Thursday, April 28, 2011. ... InterMune at 8:30 a.m. Eastern time that same day. ... 706-643-9223 (international), conference ID# 62213806.  To access the webcast, please ...
... Eigen is the proud recipient of two grant awards ... U.S. Department of Health & Human Services. QTDP tax credits ... (IRC), enacted as part of the Patient Protection and Affordable ... $244,000 award for each grant awarded in October, 2010, and ...
Cached Biology Technology:AAPC Lowers Prices on Medical Coding Books, Again 2Eigen Receives Two Grant Awards from U.S. Department of Health & Human Services 2
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... select partners? Darwin,s initial idea that the fittest males ... likely to secure partners has represented a cornerstone of evolutionary ... 1871. Darwin proposed that secondary sexual characteristics enabled females ... best for every female. This male would be the ...
... three percent (n=181) of patients in the study cohort ... their arthritis developed a first cancer within nine years ... of arthritis. The nine year follow-up study conducted ... ((RR)=1.03 (95%confidence interval 0.82-1.30)) was not increased in patients ...
... Scientists from the University of Warwick have discovered ... be ,ultra-bad, leading to increased risk of heart disease. ... heart disease particularly in people with type 2 diabetes ... British Heart Foundation (BHF), found that ,ultrabad, cholesterol, called ...
Cached Biology News:The importance of 'inner values' -- female sparrows test the genetic make-up of their mates 2Arthritis patients taking newer treatments do not have an overall increased cancer risk 2Super-sticky 'ultra-bad' cholesterol revealed in people at high risk of heart disease 2
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
... Ambions MAXIscript In Vitro Transcription Kits synthesize ... x 10 9 cpm/g. High specific ... ribonuclease protection assays, in situ hybridization, and ... used for the synthesis of modest amounts ...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Request Info...
Biology Products: